Findings reveal the potential of semaphorin levels in diagnosing myasthenia gravis, suggesting new treatment targets.
Our findings suggest that the levels of semaphorin 4A and 7A may not only support the diagnosis of MG and aid in differential diagnosis but also shed light on the development of future therapeutic protocols targeting semaphorin proteins and receptors in other autoimmune and inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Kotan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: